



Lecithin cholesterol acyltransferase (LCAT) activity in the presence of Apo-AI-derived peptides exposed to disorder–order conformational transitions



S.L. Aguilar-Espinosa^a, P. Mendoza-Espinosa^a, B. Delgado-Coello^a, J. Mas-Oliva^{a,b,*}

^aDepartamento de Bioquímica y Biología Estructural, Instituto de Fisiología Celular, Universidad Nacional Autónoma de México, Mexico DF, Mexico

^bDivisión de Investigación, Facultad de Medicina, Universidad Nacional Autónoma de México, 04510 Mexico DF, Mexico

ARTICLE INFO

Article history:

Received 9 October 2013

Available online 26 October 2013

Keywords:

Plasma LCAT activity

Apo-AI

Cholesterol metabolism

Peptide conformational change

Secondary structural transitions

Lysophospholipid

ABSTRACT

Although the association of Apo AI with HDLs has been proposed to activate LCAT activity, the detailed molecular mechanisms involved in the process are not known. Therefore, in this study we have investigated how conformational changes in several exposed regions of Apo-AI might cause LCAT activation and for this purpose, designed a strategy to investigate three Apo AI-derived peptides. Since these peptides present the ability to adopt several secondary structure conformations, they were used to determine whether LCAT activity could be modulated in the presence of a particular conformation. Circular dichroism experiments showed that Apo AI-derived peptides in PBS displayed a disordered arrangement, with a strong tendency to adopt β -sheet and random conformational structures as a function of concentration. However, in the presence of Lyso-C₁₂PC, maximal percentages of α -helical structures were observed. Performed in human plasma, time-course experiments of LCAT activity under control conditions reached the highest level of ³H-cholesteryl esters after 2.5 h incubation. In the presence of Apo AI-derived peptides, a significant increase in the production of ³H-cholesteryl esters was observed. The present study provides an important insight into the potential interactions between LCAT and lipoproteins and also suggests that peptides, initially present in a disordered conformation, are able to sense the lipid environment provided by lipoproteins of plasma and following a disorder-to-order transition, change their conformation to an ordered α -helix.

© 2013 Elsevier Inc. All rights reserved.

1. Introduction

Lecithin cholesterol acyltransferase (LCAT) is a key enzyme that catalyzes the synthesis of most of plasma cholesteryl esters. The reaction catalyzed by LCAT involves the transfer of an acyl group in the sn-2 site of phosphatidylcholine to the 3- β -hydroxyl group of cholesterol, which yields lysophosphatidylcholine and cholesterol-ester products. Cholesterol esters produced by this pathway are transported to the core of high-density lipoproteins (HDLs). Therefore, LCAT has a relevant role in the maturation of discoidal HDLs to spherical HDLs [1].

Human pre- β_1 HDL consists of a phosphatidylcholine bilayer with 47.5% apolipoprotein AI (Apo AI), 44.6% phospholipids, and 7.6% free cholesterol [2]. HDLs in plasma receive phospholipids, cholesterol, and apolipoproteins from chylomicrons and very

low-density lipoproteins (VLDLs). HDLs accumulate cholesterol esters, causing them to grow and adopt spherical shapes, HDL₃ or HDL₂, which contain up to 19% esterified cholesterol. The process of cholesterol uptake carried out by HDLs from peripheral tissues, known as reverse cholesterol transport, is an important mechanism in the prevention of cholesterol accumulation in the intima of arteries [3].

Apo AI accounts for 70% of total HDL protein [4], and the anti-atherogenic effects of Apo AI have been demonstrated in animal models and humans [5,6]. In humans, mature Apo AI is a 243-residue polypeptide [7] containing a series of highly homologous 11- and 22-residue amphipathic α -helices. These repeats comprise the amino acid region 44–243, which is a lipid-binding domain [8]. The first 43 residues of the N-terminal region are relatively disordered [9], which may stabilize the lipid-free Apo AI conformation [10]. The central region of Apo AI (residues 159–180) protrudes from discoidal HDL particles [11], where the exposed loops have been considered potential sites for LCAT interaction [12].

In our group we have investigated the disorder-to-order and order-to-disorder conformational transitions that occur when apolipoproteins are exposed to air/water interfaces [13,14]. It has been

* Corresponding author at: Instituto de Fisiología Celular, Universidad Nacional Autónoma de México, Apartado Postal 70-243, C.P. 04510 Mexico DF, Mexico. Fax: +52 55 56225584.

E-mail addresses: sandraluz_ae_qfb@yahoo.com.mx (S.L. Aguilar-Espinosa), pmendoza@email.ifc.unam.mx (P. Mendoza-Espinosa), bdelgado@ifc.unam.mx (B. Delgado-Coello), jmas@ifc.unam.mx (J. Mas-Oliva).

hypothesized that lateral pressure exerted on the phospholipid monolayer of nascent HDLs diminishes when the particles enlarge and turn into spherical lipoproteins. This pressure reduction may change the conformations of apolipoproteins and probably the functions they exert at the surface of lipoproteins [15]. We have also shown that several carboxy-end lipid-binding proteins change from non-structured conformations to well-structured α -helices in the presence of amphiphatic lipid molecules following disorder-to-order transitions [16].

Although the association of Apo AI with HDLs has been proposed to activate LCAT activity [17,18], the molecular mechanisms involved are not known. Therefore, in this study we have investigated how conformational changes in several exposed regions of Apo-AI might cause LCAT activation, and designed a strategy to investigate three Apo AI-derived peptides. Since these peptides present the ability to adopt several secondary structure conformations, we used them to determine whether LCAT activity could be modulated in the presence of a particular secondary structure. We defined that peptides in an α -helix conformation present the structural ability to maintain and enhance LCAT activity.

2. Materials and methods

Salts, buffers, bovine serum albumin (BSA), and cholesterol were purchased from Sigma (St. Louis, MO). Lauryl-2-hydroxy-sn-glycero-3-phosphocholine (Lyso-C₁₂PC) in chloroform was purchased from Avanti Polar Lipids Inc. (Alabaster, AL). Digitonin was purchased from Calbiochem (Darmstadt, Germany) and [³H]-cholesterol (20 Ci/mmol) in ethanol was purchased from American Radiolabeled Chemicals (St. Louis, MO). The liquid scintillation cocktail UniverSol ES was obtained from MP Biomedicals (Solon, OH, USA). Peptides used in this study were designed based on the reported sequence for Apo AI and synthesized with purities >98% by the GenScript Corporation (Piscataway, NJ). Peptides were named after the first amino acids of their primary sequence; DRV represents the N-terminal segment (amino acids 9–24), KLL the initial portion of the central segment (amino acids 45–63), and VLES the C-terminal segment (amino acids 221–239). Human plasma was obtained from healthy subjects from the Centro Médico Nacional 20 de Noviembre (ISSSTE, Mexico DF). Samples were stored at –70 °C and used before 3 weeks.

2.1. *In silico* analyses of Apo AI and Apo AI-derived peptides

The hydrophobicity profile of Apo AI was analyzed using the Pepinfo algorithm on the EMBOSS server. A window of 9 amino acids and the Kyte and Doolittle hydrophobicity scale were used [19]. Hydrophobic segments were predicted based on the secondary structure of the polypeptide chain of Apo AI using the hydrophobic cluster analysis server [20]. In addition, multiple alignments of human Apo AI with orthologs in other species were obtained using Clustal W 1.7 with default parameters [21]. The Pfam database was used to choose a small set of representative members from each family [22].

2.2. Circular dichroism (CD) experiments

Lyophilized peptides were reconstituted in PBS buffer (pH 7.4) for CD experiments in aqueous conditions. To carry out experiments in solutions containing Lyso-C₁₂PC, chloroform was evaporated, and 30, 60, and 90 mM solutions were prepared in water. For several experiments, a molar ratio of peptide to lipid of 1:200 was used. Peptides for CD experiments and LCAT activity measurements were prepared at final concentrations of 0.3, 0.6, and 0.9 mg/mL and incubated for 24 h at room temperature in the dark. CD

spectra were recorded with a Dichroism Spectrometer model 62DS from Aviv Biomedical, Inc. (Lakewood, NJ, USA) at 25 °C employing far-UV wavelengths (260–190 nm).

Experiments were performed in a 0.01-cm path-length cell. Spectra were recorded with a 1-mm bandwidth using 1-nm increments and 2.5-s accumulation time. CD spectra were signal averaged by adding 2–5 scans, baseline corrected, and smoothed. CD measurements were reported as a mean of ellipticity in degrees centimeter squared per decimol (deg cm² dmol⁻¹) using the AVIV 2.94 software. The secondary structure content of peptides was calculated in a wavelength range of 260–195 nm using both the neural network based CDNN software [23] in the simple spectral analysis mode and the CDPro package, which includes the SELCON3, CDSSTR, and CONTIN software packages [24].

2.3. LCAT activity measurements

Peptides used in the LCAT activity assays were prepared from stock solutions to obtain final concentrations of peptides and lipids in plasma in a final volume of 10 μ l. Before LCAT activity assays were performed, peptide–lipid mixtures were incubated at room temperature for 1 h. LCAT activity was measured according to a modified procedure described by Glomset and Wright [1]. Briefly, the procedure utilized a substrate of heat-inactivated human plasma lipoproteins equilibrated with [³H]-cholesterol plus albumin inactivated plasma (1:8:1 v/v). After heating human plasma at 60 °C for 30 min, the substrate was recovered by centrifugation at 13,200 rpm for 3 min in a refrigerated 5415R Eppendorf microfuge (rotor F45-24-11). Inactivated plasma was labeled with a stabilized cholesterol emulsion prepared by adding 1 nmol of [³H]-cholesterol/ μ l of the preparation to one volume of 5% BSA in 150 mM NaCl. Eight volumes of inactivated plasma were added to the cholesterol emulsion and incubated at 37 °C for 2–4 h.

To start the enzyme activity assays, the substrate was mixed with one volume of enzyme in a final volume of 100 μ l. After incubation at 37 °C, the reaction was stopped with 800 μ l of 1% digitonin (in 95% ethanol) and 40 μ l of 5 mg/mL cholesterol [25]. Samples were vigorously mixed and centrifuged at 6000 rpm for 10 min in a Beckman microfuge. [³H]-cholesteryl esters produced by LCAT were measured in 0.8-mL aliquots of the supernatant plus 3 mL of liquid scintillation cocktail. LCAT activity was reported as pmol of the [³H]-cholesterol esterified product/h/mL of plasma.

2.4. Statistics

Statistical analyses were performed by ANOVA using GraphPad Prism 6.0c (GraphPad Software, Inc.). Tukey's test was performed to study the significance of differences between the control and the Apo AI-derived peptides treated samples. Data were expressed as mean \pm SEM. $P < 0.05$ was considered statistically significant.

3. Results and discussion

3.1. Physicochemical characterization of Apo AI-derived peptides

To uncover whether structural transitions of Apo AI could activate LCAT, the physicochemical characterization of Apo AI and Apo AI-derived peptides was carried out. The *in silico* analysis of Apo AI showed a hydrophobicity profile with negative values present at the N- and C-terminal regions of the protein (amino acid segments 10–17 and 213–229). Positive values indicating hydrophobic zones were found in 3 clusters (amino acid segments 13–22, 45–49, and 216–232) where peptides designed for this study are also located (Fig. 1A). This hydrophobicity pattern is compatible with the interaction between Apo AI and discoidal HDL particles, where the N




Fig. 1. Physicochemical analyses of Apo AI and Apo AI-derived peptides DRV, KLL, and VLES. (A) Hydrophobicity profile and hydrophobic clusters obtained in EMBOSS (orange boxes). (B) Helical wheel representation of Apo AI-derived peptides with their corresponding μH values. The amphipathic nature of the peptides is shown with the line indicating the polar–nonpolar interface. Black: hydrophobic residues, blue: basic residues, red: acidic residues, and yellow: polar uncharged residues. (C) Alignment of the amino acid sequence of DRV, KLL, and VLES peptides with orthologs in other species. Conserved residues are indicated.

and C-ends of Apo AI might be relevant to lipid recognition domains. Previous studies have indicated that the N-terminus of a lipid-free Apo AI is involved in the control between the opened (horseshoe-like) or closed status of the protein, and that the C-terminus facilitates its anchoring to lipid membranes [26,27].

As part of the physicochemical analysis of these peptides, their amphiphilicity was also estimated (Fig. 1B). DRV presented the highest hydrophobic moment value (μH) of 490 kcal/mol, followed by VLES and KLL ($\mu H = 0.390$ and 0.280 kcal/mol, respectively). A helical wheel representation shows that DRV and VLES presented a more asymmetrical distribution of polar and non-polar amino acids than KLL, confirming their amphiphilic properties (Fig. 1B). Since μH values >0.2 kcal/mol were found in all peptides studied, they can be considered as good candidates to form amphipathic helices [28].

In addition, the analyses performed to determine the sequence–structure–function relationship of these Apo AI-derived peptides, suggest a relevant and phylogenetically conserved function (Fig. 1C).

3.2. Circular dichroism experiments

CD experiments showed that Apo AI-derived peptides in PBS displayed a disordered arrangement, with a strong tendency to adopt β -sheet and random conformational structures as a function

of concentration (Fig. 2A). This phenomenon was reflected on the solubility of peptides at high concentrations. KLL, the most hydrophilic peptide, was soluble in PBS even at high concentrations, whereas VLES, the most hydrophobic one, was difficult to dissolve even at low concentrations. According to previous work performed by our group, when amphipathic lipids are used beyond to their critical micelle concentration in a mol:mol ratio of 1:200 (peptide:Lyso- $C_{12}PC$), it is possible to obtain organized peptide/lipid arrangements and therefore solubility achieved [16]. Based on these data, we used peptide concentrations of 0.3, 0.6, and 0.9 mg/mL dissolved in solutions containing 30, 60, and 90 mM lysophospholipid. When compared to results obtained using PBS solutions, maximal percentages of α -helical structures were observed in the presence of 30 mM Lyso- $C_{12}PC$. DRV increased its α -helix content from 19.7% to 34.5%, KLL from 17% to 31.3%, and VLES from 16.4% to 30.2% (Table 1). However, there was a loss of ordered structures as a function of peptides concentration (Fig. 1B, Table 1). A similar trend was found in experiments with peptide solutions at a constant 30 mM Lyso- $C_{12}PC$ concentration (data not shown). Therefore, the maximal content of α -helical structures was obtained at a peptide concentration of 0.3 mg/mL containing 30 mM Lyso- $C_{12}PC$, suggesting that the structural arrangement of the three peptides depends not only on peptide concentration, but on the presence of a specific lipid concentration at which optimal ordered structures are reached.




Fig. 2. CD spectra of the Apo AI-derived peptides at different concentrations. (A) In PBS, pH 7.4. (B) In peptide:Lyso-C₁₂PC ratios of 1:200 (mol:mol); 0.3, 0.6 and 0.9 mg/mL peptide in 30, 60 and 90 mM Lyso-C₁₂PC, respectively.

Table 1

Percentages of α -helical content of Apo-AI derived peptides solutions dissolved either in PBS (pH 7.4) or in Lyso-C₁₂PC in a mol/mol ratio 1:200 (peptide:lipid), determined by circular dichroism spectroscopy.

	α Helix/PBS (%)			α Helix/Lyso-C ₁₂ PC (%)		
Lyso-C ₁₂ PC (mM)	0.0	0.0	0.0	30.0	60.0	90.0
Peptide (mg/mL)	0.3	0.6	0.9	0.3	0.6	0.9
DRV	19.7	20.0	18.2	34.5	29.9	25.9
KLL	17.0	17.2	15.9	31.3	26.2	20.6
VLES	16.4	16.9	17.0	30.2	22.9	19.9

3.3. Effect of Apo AI-derived peptides on LCAT activity

To our knowledge, this is the first study where several interventions designed in order to modulate LCAT activity, is directly measured in plasma, considered its natural environment. Under these conditions, plasma LCAT activity was measured in the presence of all three Apo AI-derived peptides reconstituted in PBS or Lyso-C₁₂PC solutions. Time course experiments of LCAT activity under control conditions showed the highest enzyme activity increase after 2.5 h of incubation and the maximal product yield was obtained up to 5 h. Therefore, this time was used to calculate the

highest production of ³H-cholesteryl esters in the subsequent plasma LCAT activity assays (Fig. 3). When plasma was tested in the presence of Apo AI-derived peptides at 0.3 and 0.6 mg/mL in PBS, a significant increase in ³H-cholesteryl esters production was observed (Fig. 3A and B, respectively). It is evident that LCAT activity was stimulated in a higher proportion at 0.3 mg/mL (Fig. 3A) in comparison to 0.6 mg/mL peptide solutions (Fig. 3B). According to these results and considering the hydrophobic properties of peptides tested, it is possible that stimulation of LCAT activity in their presence is related to their ability to bind lipids and to adopt and maintain an α -helical conformation.

To confirm this hypothesis we suspended the peptides in different lipid solutions and tested their abilities to activate LCAT. Assays containing a mol:mol ratio of 1:200 (peptide:Lyso-C₁₂PC) showed that plasma LCAT activity was fully abolished at peptide concentrations >0.3 mg/mL in 30 mM Lyso-C₁₂PC (Fig. 4A). Control experiments performed in the absence of peptides indicated that the lysophospholipid itself showed an inhibitory effect on the LCAT activity at concentrations higher than 30 mM (Fig. 4A). Several explanations involving product inhibition by lysophospholipids and cholesteryl esters have been proposed. It is also possible that detergent effects might be involved [29] and that the surfactant




Fig. 3. Time course of LCAT activity in the presence of Apo-AI-derived peptides in PBS (pH 7.4). (A) At 0.3 mg/mL and (B) At 0.6 mg/mL. Each point represents the mean of quantifications performed in triplicate \pm SEM. * Significant $P \leq 0.01$; ** significant $P \leq 0.0001$, compared to plasma control.




Fig. 4. Effects of Apo AI-derived peptides in the presence of Lyso- $C_{12}PC$ on LCAT activity. (A) In a ratio peptide/Lyso- $C_{12}PC$ of 1:200 (mol:mol). (B) Activity measured at a constant Lyso- $C_{12}PC$ concentration (30 mM). Each point represents the mean of quantifications performed in triplicate \pm SEM. * Significant $P \leq 0.01$; ** significant $P \leq 0.0001$, compared to plasma control.

properties of the lysophospholipid promote the solubilization of the substrates including HDLs and LDLs and preclude enzyme interaction [30]. Another possibility is that lysophospholipids compete with free cholesterol inhibiting the lysolecithin acyl transferase activity of LCAT [31,32].

Under our experimental conditions, inhibition was observed even in the presence of Apo AI peptides, indicating that they were unable to revert the lysophospholipid effect. This finding may be

explained by the loss of α -helical conformation associated with a higher concentration of peptides in the presence of high Lyso- $C_{12}PC$ concentrations (Fig. 2B, Table 1). Due to the inhibitory effect observed on LCAT activity followed by the presence of high lysophospholipid concentrations, we changed the peptide concentrations and maintained a Lyso- $C_{12}PC$ concentration of 30 mM. This set of experiments showed that plasma LCAT activity was maintained in the presence of the three peptides, even at concentrations

Table 2Quantification of [³H]-cholesteryl esters produced by plasma LCAT at 5 h of incubation in the presence of Apo-AI-derived peptides in PBS (pH 7.4).

Condition		[³ H]-cholesteryl esters (pmol)	Increase over control (%)
Plasma		0.92 ± 0.06	–
DRV	0.3 mg/mL	1.35 ± 0.08	47.03**
	0.6 mg/mL	1.16 ± 0.04	26.46**
KLL	0.3 mg/mL	1.38 ± 0.03	50.08**
	0.6 mg/mL	1.12 ± 0.12	21.92**
VLES	0.3 mg/mL	1.29 ± 0.13	40.12**
	0.6 mg/mL	0.99 ± 0.07	7.51*

Absolute values determined ± SEM. – Not Applicable

* Significant $P \leq 0.01$.** significant $P \leq 0.0001$.

between 0.6 and 0.9 mg/mL but with no significant differences among them (Fig. 4B). Consistent with our previous results, a high peptide concentration was associated with the loss of helical structure (Fig. 2B, Table 1) and a decrease in LCAT activity (Fig. 3B). Therefore, structural arrangements of peptides and the conservation of plasma LCAT activity were favored in the presence of specific Lyso-C₁₂PC concentration, independent of peptide sequence (Table 2).

Concerning the mechanism involved in the modulation of peptides tested upon LCAT activity, it has been suggested that α -helices modify the water/phospholipid interfaces in order to expose the substrate at the active site of LCAT [33]. Our group has shown that Apo AI and other exchangeable apolipoproteins can be maintained at the air/water interface in Langmuir pans where they are able to undergo conformational changes due to increments in lateral pressure [16]. These observations suggest that when HDLs are in a discoidal lipid-poor form, apolipoproteins are exposed to high pressures. While HDLs increase their size due to the accumulation of cholesteryl esters, apolipoproteins increase freedom of movement and respond better to microenvironmental conditions [17]. Experimentally, we observed that a segment of Apo CI reacted to lateral pressures by changing their unstructured conformation to a more ordered α -helical conformation [18]. These findings might suggest that disorder-to-order transitions are dependent on medium composition [18]. Likewise, our present results show that the conformational transitions of peptides modulated by the surrounding lipid environment are also important in the maintenance of LCAT enzyme activity.

The present study provides an important insight into the potential interactions between LCAT and lipoproteins and also suggests that peptides, initially present in a disordered conformation, when in contact with the reaction mixture are able to sense the lipid environment provided by lipoproteins of plasma and change to an ordered α -helical conformation. Then, when peptides adopt a more efficient conformation following disorder-to-order transitions, they are able to increase LCAT activity. Moreover, subtle changes in activation can be related to specific characteristics of the peptides, such as amphiphilicity and the capacity to bind lipids. Accordingly, peptides with a high μ H and high affinity for lipid surfaces were more potent activators of LCAT activity. Another relevant finding was that the concentration of the activator should be precisely controlled to attain the expected disorder-to-order transition.

Acknowledgments

This work was supported by the DGAPA-UNAM (Grants IN-205711/2 and RR205711) awarded to J.M.-O. The authors thank José Gutiérrez-Salinas for the human plasma samples. SLAE was supported by a fellowship by the Consejo Nacional de Ciencia y Tecnología (CONACyT) for M. Phil. studies.

References

- J. Glomset, J. Wright, Some properties of a cholesterol esterifying enzyme in human plasma, *Biochem. Biophys. Acta* 89 (1968) 266–276.
- M. Wróblewska, The origin and metabolism of a nascent pre- β -high density lipoprotein involved in cellular cholesterol efflux, *Acta Biochim. Pol.* 58 (2011) 275–285.
- K. Mahdy Ali, A. Wonnerth, K. Huber, J. Wojta, Cardiovascular disease risk reduction by raising HDL cholesterol – current therapies and future opportunities, *Br. J. Pharmacol.* 167 (2012) 1177–1194.
- G.F.Y. Lewis, D.J. Rader, New insights into the regulation of HDL metabolism and reverse cholesterol transport, *Circ. Res.* 96 (2005) 1221–1232.
- E.M. Rubin, R.M. Krauss, E.A. Spangler, et al., Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI, *Nature* 353 (1991) 265–267.
- S.E. Nissen, T. Tsunoda, E.M. Tuzcu, et al., Effect of recombinant Apo-AI on coronary atherosclerosis patients with acute coronary syndromes: a randomized controlled trial, *JAMA* 290 (2003) 2292–2300.
- H.B. Brewer, T. Fairwell, A. LaRue, et al., The amino acid sequence of human Apo-AI an apolipoprotein from high density lipoproteins, *Biochem. Biophys. Res. Commun.* 80 (1978) 623–630.
- A.E. Klon, J.P. Segrest, S.C. Harvey, Comparative models for human apolipoprotein A-I bound to lipid in discoidal high-density lipoprotein particles, *Biochemistry* 41 (2002) 10895–10905.
- J.P. Segrest, M.K. Jones, H. De Loof, et al., The amphipathic helix in the exchangeable apolipoproteins: a review of secondary structure and function, *J. Lipid Res.* 33 (1992) 141–166.
- D.W. Borhani, D.P. Rogers, J.A. Engler, C.G. Brouillette, Crystal structure of truncated human apolipoprotein A-1 suggests a lipid-bound conformation, *Proc. Natl. Acad. Sci. USA* 94 (1997) 12291–12296.
- M.G. Sorci-Thomas, Activation of lecithin:cholesterol acyltransferase by HDL Apo A-I central helices, *Clin. Lipidol.* 4 (2009) 113–124.
- Z. Wu, M.A. Wagner, L. Zheng, et al., The redefined structure of nascent HDL reveals a key functional domain for particle maturation and dysfunction, *Nature* 14 (2007) 861–868.
- V. Bolaños-García, J. Mas-Oliva, S. Ramos, et al., Phase transitions in monolayers of human apolipoprotein C-I, *J. Phys. Chem. B* 103 (1999) 6236–6242.
- V. Bolaños-García, S. Ramos, J. Xicohtencatl-Cortés, et al., Monolayers of apolipoproteins at the air/water interface, *J. Phys. Chem. B* 105 (2001) 5757–5765.
- J. Xicohtencatl-Cortés, R. Castillo, J. Mas-Oliva, In search of new structural states of exchangeable apolipoproteins, *Biochem. Biophys. Res. Commun.* 324 (2004) 467–470.
- P. Mendoza-Espinosa, A. Moreno, R. Castillo, J. Mas-Oliva, Lipid dependant disorder-to-order conformational transitions in apolipoprotein CI derived peptides, *Biochem. Biophys. Res. Commun.* 365 (2008) 8–15.
- C.J. Fielding, V.G. Shore, P.E. Fielding, A protein cofactor of lecithin cholesterol acyltransferase, *Biochem. Biophys. Res. Commun.* 46 (1972) 1493–1498.
- A. Jonas, Lecithin cholesterol acyltransferase, *Biochim. Biophys. Acta* 1529 (2000) 245–256.
- J. Kyte, R.F. Doolittle, A simple method for displaying the hydropathic character of a protein, *J. Mol. Biol.* 157 (1982) 105–132.
- I. Callebaut, G. Labesse, P. Durand, et al., Deciphering protein sequence information through hydrophobic cluster analysis (HCA): current status and perspectives, *Cell. Mol. Life Sci.* 53 (1997) 621–645.
- J.D. Thompson, D.G. Higgins, T.J. Gibson, Clustal W: improving the sensitivity of progressive multiple sequences alignment through sequence weighting, position-specific gap penalties and weight matrix choice, *Nucleic Acids Res.* 22 (1994) 4673–4680.
- M. Punta, P.C. Coghill, R.Y. Eberhardt, et al., The Pfam protein families database, *Nucleic Acids Res.* 40 (D1) (2012) D290–D301.
- B. Dalmas, G.J. Hunter, W.H. Bannister, Prediction of protein secondary structure from circular dichroism spectra using artificial neural network techniques, *Biochem. Mol. Biol. Int.* 34 (1994) 17–26.

- [24] N. Sreerama, R.W. Woody, Estimation of protein secondary structure from circular dichroism spectra: comparison of CONTIN, SELCON and CDSSTR methods with an expanded reference set, *Anal. Biochem.* 287 (2000) 790–797.
- [25] U. Piran, R.J. Morin, A rapid radioassay procedure for plasma lecithin cholesterol acyltransferase, *J. Lipid Res.* 20 (1979) 1040–1043.
- [26] Y. Fang, O. Gursky, D. Atkinson, Lipid-binding studies of human apolipoprotein A-I and its terminally truncated mutants, *Biochemistry* 42 (2003) 13260–13268.
- [27] M. Kono, Y. Okumura, M. Tanaka, et al., Conformational flexibility of the N-terminal domain of apolipoprotein A-I bound to spherical lipid particles, *Biochemistry* 47 (2008) 11340–11347.
- [28] M.K. Jones, G.M. Anantharamaiah, J.P. Segrest, Computer programs to identify and classify amphipathic α helical domains, *J. Lipid Res.* 33 (1992) 287–296.
- [29] N.B. Smith, A. Kuksis, Stereochemical substrate requirements of lecithin:cholesterol acyltransferase and its inhibition by enantiomeric lysolecithins, *Can. J. Biochem.* 58 (1980) 1286–1291.
- [30] R.E. Stafford, E.A. Dennis, Lysophospholipids as biosurfactants, *Colloids Surf.* 30 (1988) 47–64.
- [31] P.V. Subbaiah, Lysolecithin acyltransferase of human plasma: assay and characterization of enzyme activity, *Methods Enzymol.* 129 (1986) 790–797.
- [32] M. Liu, P.V. Subbaiah, Activation of plasma lysolecithin acyltransferase reaction by apolipoproteins A-I, C-I and E, *Biochim. Biophys. Acta* 1168 (1993) 144–152.
- [33] F.S. Bonelli, A. Jonas, Reaction of lecithin cholesterol acyltransferase with water-soluble substrates, *J. Biol. Chem.* 264 (1989) 14723–14728.